Chinese biotech giant WuXi AppTec’s shares jump after Pentagon blacklist reversal

WuXi AppTec, a prominent Chinese biotech firm, experienced a surge in its shares on Tuesday following the Pentagon's decision to remove it from a blacklist linked to alleged military connections. The move, announced in a Federal Register notice, saw the company's shares rise over 6% at the opening bell in Hong Kong, before settling around a 2% increase in early trading.

WuXi AppTec's Shanghai-listed shares also climbed approximately 1.8%. In a filing, the company expressed relief from potential adverse consequences stemming from the 1260H designation. Originally added to the Section 1260H list in June, the designation impeded federal procurement and exposed targeted firms to broader restrictions and market risks.

WuXi AppTec had vowed to pursue legal remedies against the designation, filing a lawsuit against the US Department of Defense in June. Jialin Zhang, a China healthcare research head at Nomura, viewed the removal as a "positive geopolitical development" that might alleviate investor concerns. Citi also noted that the delisting could boost the company's stock value and the overall sentiment of the Chinese contract service sector.

The Pentagon's delisting of WuXi AppTec was a result of a US District Court for the District of Columbia ruling, which barred the Pentagon from enforcing the designation in a preliminary injunction. Chief Judge James Boasberg criticized the Pentagon's reasoning, deeming it "arbitrary and capricious." While the delisting marked a significant victory for WuXi AppTec and other Chinese firms facing similar US blacklists, the possibility of the company being re-added to the list remains, as Zhang explained.

Other Chinese entities, such as chip-equipment maker Advanced Micro-Fabrication Equipment and Xiaomi, have previously been removed from the list and won their lawsuits against the Pentagon.